Latest News

January 2018

Available now: Language versions of "Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016​"

The Surviving Sepsis Campaign (SSC) have made the 2016 Guidelines available now in Arabic, Chinese, French, Japanese, Portuguese and Spanish.  

Find the language versions of the SSC Guidelines here >
Find out more on B·R·A·H·M·S PCT for early detection of sepsis >


December 2017

Practical Patient Care - Issue 20 / 2017

Procalcitonin for neonatal sepsis diagnosis and safe antibiotic guidance 

Neonatal infections remain a challenge for today's physicians, as early signs and symptoms are often protean and non-specific. B·R·A·H·M·S PCT can help to detect neonatal sepsis and assist in safe antibiotic guidance. 

Read the full article on Practical Patient Care >
Find out more on B·R·A·H·M·S PCT in Neonatal sepsis >


November 2017

Kampala Declaration - African Sepsis Alliance 

The African Sepsis Alliance (ASA) works to reduce the impact of sepsis (mortality and suffering) by initiating large scale improvements in sepsis awareness, education, care, research and funding throughout Africa.
In cooperation with the African Federation of Critical Care Nurses, Global Sepsis Alliance and World Federation of Critical Care Nurses the ASA put together the Kampala Declaration to improve care for sepsis and severely ill patients in Africa.

Read the Kampala Declaration >
Find out about the African Sepsis Alliance >
Sign the Kampala Declaration on change.org >


November 2017

10th European Antibiotic Awareness Day 

15 November 2017 marks the 10th European Antibiotic Awareness Day, an EU-level initiative to raise awareness about the threat to public health of antimicrobial resistance (AMR) and the importance of using antibiotics prudently.  

More on European Antibiotic Awareness Day 2017 >
Do watch the video of the live web-conference "Keeping Antibiotics Working" on YouTube >
Read more on antibiotic stewardship >


November 2017

NeoPInS - The largest intervention study in neonates for shortening of antibiotic therapy 

The recently published multicentric, multinational randomized controlled NeoPIns study shows a 15% reduced duration of antibiotic therapy guided by Procalcitonin (55 hrs vs. 65 hrs) and a shorter hospital stay in a large cohort of neonates with suspected early-onset sepsis. With 1710 neonates, NeoPIns is the largest randomized intervention study till date for shortening of antibiotic treatment in neonates.

Read it on The Lancet >
Find out more on B·R·A·H·M·S PCT in Neonatal sepsis >


November 2017

World Antibiotic Awareness Week (WAAW) 2017

This year's WAAW-theme: Seek advice from a qualified healthcare professional before taking antibiotics. Antibiotics are a precious resource, so it is important to get the right advice before taking them. Responsible use of antibiotics will also help reduce the threat of antibiotic resistance.

Find out more on WAAW 2017 >
Read more on antibiotic stewardship >


August/September 2017

Sepsis Media Award 2017 of the German Sepsis Society

Every year, outstanding works of medical journalism to increase knowledge and awareness about sepsis in German-speaking countries receive recognition by the German Sepsis Society (DSG)

The 2017 Sepsis Media Award will be announced during the opening meeting of the "Sepsis Update" in Weimar on Sep 6, 2017.

 Sponsor of the Sepsis Media Award is Thermo Fisher Scientifc.

Read more > about previous winners of the Sepsis Media Award
Find out > about Sepsis Update 2017


June 2017

Recognizing Sepsis as a Global Health Priority - A WHO Resolution

The World Health Organization (WHO) recognizes the priority on improving prevention, diagnosis and management of sepsis globaly. Millions of lives can be saved if politicians, policymakers, health care administrators, researchers, and clinicians take coordinated efforts.

Read more > in The NEW ENGLAND JOURNAL of MEDICINE (NEJM)


May 2017

Time to Treatment and Mortality during Mandated Emergency Care for Sepsis

In 2013, New York began requiring hospitals to follow protocols for the early identification and treatment of sepsis. However, there is controversy about whether more rapid treatment of sepsis improves outcomes in patients.

Time to Treatment and Mortality during Mandated Emergency Care for Sepsis ›


April 20, 2017

Multi-Center Clinical Study Confirms Decreased Levels of Procalcitonin as an Independent Predictor of Mortality in Patients with Severe Sepsis and Septic Shock

Results from Procalcitonin MOnitoring SEpsis Study published in May 2017 issue of Critical Care Medicine

Multi-Center Clinical Study Confirms Decreased Levels of Procalcitonin as an Independent Predictor of Mortality in Patients with Severe Sepsis and Septic Shock ›


February 2017

FDA clears test to help manage antibiotic treatment for lower respiratory tract infections and sepsis

The U.S. Food and Drug Administration today cleared the expanded use of the Vidas Brahms PCT Assay...

Read more on FDA News Release ›


November 2016

Biomarkers guide safe antibiotic decisions

Overuse of antibiotics is a global problem, but the biomarker Procalcitonin (PCT), such as the B·R·A·H·M·S PCT assay from Thermo Fisher Scientific, can help guide antibiotic stewardship and reduce resistance to the effects of these drugs.

Read article in Practical Patient Care ›


September 26, 2016

Thermo Fisher Scientific Joins Sepsis Alliance in Support of Sepsis Awareness Month

Sepsis Awareness Month aims to provide education around a deadly condition that is claiming millions of lives globally every year.
Thermo Fisher Scientific has joined the Sepsis Alliance and advocates to spread the word about sepsis and the risk factors associated with the condition. 

Thermo Fisher Scientific Joins Sepsis Alliance in Support of Sepsis Awareness Month ›


July 7, 2016

Innovative trial design helps accelerate FDA clearance process for B·R·A·H·M·S PCT license partners

An innovative trial design helped our license partners, Roche Diagnostics USA and bioMérieux, achieve FDA clearance in just 90 days for the Roche ELECSYS B·R·A·H·M·S PCT and bioMérieux VIDAS B·R·A·H·M·S PCT assays. The Procalcitonin MOnitoring SEpsis Study (MOSES) included 858 adult patients with sepsis recruited across 13 investigational sites in the U.S.

B·R·A·H·M·S PCT license partners achieve FDA clearance in 90 days ›

www.mddionline.com > A Diagnostic Trial Designed to Speed Clearance ›


June 23, 2016

Roche receives FDA clearance for Elecsys B·R·A·H·M·S PCT

Roche announced that it has received 510(k) clearance for its Elecsys B·R·A·H·M·S PCT (Procalcitonin) assay as a dedicated testing solution for people with severe sepsis or septic shock.

www.prnewswire.com > Roche receives FDA clearance for its Procalcitonin (PCT) assay to help clinicians effectively assess sepsis risk and manage sepsis patients ›


March 1, 2016

Expanded FDA clearance for B·R·A·H·M·S PCT sepsis biomarker

Thermo Fisher Scientific Inc. has received clearance from the U.S. Food and Drug Administration (FDA) that expands the clinical claims of the Thermo Scientific B·R·A·H·M·S PCT (Procalcitonin) biomarker assay for sepsis risk assessment. Clinicians can now use B·R·A·H·M·S PCT to help assess the response of septic patients to treatment by comparing a baseline PCT measurement with a PCT value taken on day four.

B·R·A·H·M·S PCT cleared for assessing mortality risk of septic patients ›

thermo scientific applied biosystems invitrogen fisher scientific unity lab service